🇺🇸 DepoCyte in United States

112 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Headache — 18 reports (16.07%)
  2. Pyrexia — 17 reports (15.18%)
  3. Deafness — 12 reports (10.71%)
  4. Arachnoiditis — 11 reports (9.82%)
  5. Granulomatous Liver Disease — 11 reports (9.82%)
  6. Febrile Neutropenia — 10 reports (8.93%)
  7. Thrombocytopenia — 10 reports (8.93%)
  8. Confusional State — 8 reports (7.14%)
  9. Off Label Use — 8 reports (7.14%)
  10. Haematotoxicity — 7 reports (6.25%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is DepoCyte approved in United States?

DepoCyte does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for DepoCyte in United States?

PETHEMA Foundation is the originator. The local marketing authorisation holder may differ — check the official source linked above.